Table 2.
Clinical trials for epigenetic therapies in prostate cancer
| Mechanism | Clinical trial ID | Agent | Phase | Indication | Clinical status |
|---|---|---|---|---|---|
| EZH2 inhibition | NCT03009344 | Tazemetostat | I | Relapsed or refractory B-cell non-Hodgkin’s lymphoma | Active, not recruiting |
| NCT02875548 | Tazemetostat | II | Diffuse large B-cell Lymphoma; advanced solid tumors | Completed | |
| NCT04179864 | Tazemetostat + abiraterone/prednisone tazemetostat + enzalutamide |
I | mCRPC | Recruiting | |
| NCT03460977 | PF-06821497 | I | Relapsed/refractory SCLC, CRPC, and follicular lymphoma | Recruiting | |
| NCT02395601 | CPI-1205 | I | B-Cell lymphomas | Completed | |
| NCT03480646 | CPI-1205 + enzalutamide CPI-1205 + abiraterone/prednisone |
Ib/II | mCRPC | Active, not recruiting | |
| NCT01848067 | Alisertib (MLN8237) + abiraterone + prednisone | I/II | mCRPC | Completed | |
| NCT03525795 | CPI-1205 + Ipilimumab | I/II | Advanced solid tumors | Active, not recruiting | |
| N-Myc inhibition | NCT01799278 | MLN8237/alisertib | II | CRPC/NEPC | Completed; no appearance of new lesions for >1 month |
| BET inhibition | NCT02705469 | ZEN003694 | I | mCRPC | Completed; dose confirmation |
| NCT04145375 | I: ZEN003694 II: ZEN003694 + enzalutamide |
I/II | mCRPC | Enrolling by invitation | |
| NCT02711956 | I: ZEN003694 II: Enzalutamide |
Ib/IIa | mCRPC | Active, not recruiting | |
| NCT04471974 | Pembrolizumab (day 1) ZEN-3694 + enzalutamide (days 1- 21) |
II | mCRPC | Not yet recruiting (2020/8 start) | |
| NCT02607228 | GS-5829 + enzalutamide | Ib/II | mCRPC with ARPI | Completed | |
| NCT02698176 | MK-8628 | I | CRPC | Terminated | |
| LSD1 inhibition | NCT02712905 | INCB059872 | I/II | Advanced malignancies; NEPC | Terminated |
| NCT02217709 | Phenelzine | II | Nonmetastatic recurrent prostate cancer | Active, not recruiting | |
| NCT01253642 | Phenelzine + docetaxel | II | PCa with progressive disease | Terminated | |
| DNMT inhibition | NCT00384839 | Azacitidine for injectable suspension | II | PCa to hormonal therapy | Completed; PSA doubling time ≥3 months |
| NCT03572387 | 5-AZA + ATRA | Pilot study | PCa with PSA-only recurrence | Recruiting | |
| NCT00503984 | Azacitidine + docetaxel + prednisone | I/II | mPC | Terminated | |
| NCT03709550 | Enzalutamide + decitabine | Ib/II | mCRPC | Not yet recruiting (2020/8 start) | |
| NCT02998567 | Guadecitabine + pembrolizumab | I | CRPC solid tumors | Active, not recruiting |
5-AZA: 5-azacitidine, ATRA: All-trans retinoic acid, CRPC: Castration-resistant prostate cancer, mCRPC: Metastatic CRPC, DNMT: DNA methyltransferase, PCa: Prostate cancer, ARPI: Androgen receptor pathway inhibitor, BET: Bromodomain and extra-terminal motif, NE: Neuroendocrine, NEPC: NE prostate cancer, SCLC: Small-cell lung carcinoma